Free Trial
NASDAQ:ALLK

Allakos (ALLK) Stock Price, News & Analysis

$0.88
+0.03 (+3.53%)
(As of 07/24/2024 ET)
Today's Range
$0.83
$0.88
50-Day Range
$0.69
$1.45
52-Week Range
$0.68
$5.64
Volume
564,597 shs
Average Volume
913,915 shs
Market Capitalization
$77.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.67

Allakos MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
89.5% Upside
$1.67 Price Target
Short Interest
Healthy
5.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
-0.25mentions of Allakos in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$87,935 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.22) to ($0.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.35 out of 5 stars

Medical Sector

123rd out of 901 stocks

Pharmaceutical Preparations Industry

43rd out of 426 stocks

ALLK stock logo

About Allakos Stock (NASDAQ:ALLK)

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

ALLK Stock Price History

ALLK Stock News Headlines

Can Allakos (NASDAQ:ALLK) Afford To Invest In Growth?
Forecaster with 99.8% Accuracy Makes Shocking Prediction
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Forecaster with 99.8% Accuracy Makes Shocking Prediction
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
3 Biotech Stocks to Dump Before They Go to Zero
See More Headlines
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
7/24/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
131
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.67
High Stock Price Target
$3.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+89.5%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-185,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.93 per share

Miscellaneous

Free Float
74,271,000
Market Cap
$77.89 million
Optionable
Optionable
Beta
0.88
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Robert Alexander Ph.D. (Age 54)
    CEO & Director
    Comp: $1.5M
  • Dr. Adam L. Tomasi Ph.D. (Age 54)
    President
    Comp: $1.15M
  • Mr. Baird Radford III (Age 54)
    Chief Financial Officer
    Comp: $731.35k
  • Ms. Mary Cromwell Ph.D.
    Chief Technical Officer
  • Dr. Chin Lee M.D. (Age 54)
    M.P.H., Chief Medical Officer
  • Mr. Alan Chang
    Director of Medical Affairs & Data Analytics

ALLK Stock Analysis - Frequently Asked Questions

How have ALLK shares performed this year?

Allakos' stock was trading at $2.73 at the start of the year. Since then, ALLK stock has decreased by 67.8% and is now trading at $0.8797.
View the best growth stocks for 2024 here
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.09.

When did Allakos IPO?

Allakos (ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

Who are Allakos' major shareholders?

Top institutional investors of Allakos include Concourse Financial Group Securities Inc.. Insiders that own company stock include Harlan Baird Radford and Steven P James.
View institutional ownership trends
.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE) and Eastman Chemical (EMN).

This page (NASDAQ:ALLK) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners